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Abstract Calculating verisimilitude (or ‘‘truthlikeness’’)
ad modum Popper is a quantitative alternative to the usual
pros and cons in migraine and cluster headache mecha-
nisms. The following items were evaluated: dilation of
large cranial arteries during migraine; CGRP increase
during migraine; migraine as a brain disorder; aura and
migraine headache; brain stem activation during migraine;
rCBF in migraine without aura; NO and pathophysiology
of migraine; neurogenic inflammation and migraine; aura
in cluster headache; and hypothalamic activation in cluster
headache. It is concluded that verisimilitude calculations
can be helpful when judging pathophysiological problems
in migraine and cluster headache.
Keywords Migraine  Cluster headache 
Pathophysiology  Mechanism  Verisimilitude
What Hume called our ‘natural instincts’ are stronger
than any philosophical argument. In my view this
applies to science as well.
Peter Lipton, 2005 [1].
Introduction
Pathophysiological studies of migraine often involve new
techniques to reveal abnormalities compared with a control
group. Alternatively, an intervention provokes a migraine
attack [2–5], with patients assessed before and after the
intervention. Migraine research is increasingly hypothesis
driven as migraine mechanisms become better understood
[6, 7].
Philosopher of science Sir Karl Popper stated, ‘‘a good
theory…makes a number of predictions that can in prin-
ciple be disproved or falsified by observation’’ [8]. Estab-
lished methods for comparing drug effects [9] include
designing randomized clinical trials based on the null
hypothesis. Additionally, systematic reviews or meta-
analyses can estimate effects within 95% confidence
intervals (CI) [10–13]. Systematic meta-analyses are not
applicable to migraine mechanism theories and differing
results with different methodologies prevent direct com-
parisons. To deal with such situations, Popper introduced the
concept of verisimilitude (or ‘‘truthlikeness’’) [14] to score the
degree of likelihood of truth in a theory or statement. The
concept has advantages over the pros and cons that are nor-
mally used where there are disagreements, as often occur in
headache research. We applied the concept to several
important migraine and cluster headache mechanisms. This
exercise is aimed toward enlightening the migraine research
field and to indicate where further research is needed.
Methods
Verisimilitude (or ‘‘truthlikeness’’) of a theory a can be
expressed ad modum Popper [14] as:
Vs að Þ ¼ CTv að Þ  CTf að Þ
where Vs(a) is the verisimilitude of a, CTv(a) is a measure
of the truth content of a, and CTf(a) is a measure of the
falsity of a [14].
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When calculating Vs(a) in Table 1, both CTv(a) and
CTf(a) were given arbitrary values of 0, 0.25, 0.5, 0.75, or
1.0 for simplicity. The results for verisimilitude, Vs(a),
can thus be -1.0 (very unlikely), -0.75 (most unlikely),
-0.5 (unlikely), -0.25 (probably unlikely), 0 (undecided),
?0.25 (probably likely), ?0.5 (likely), ?0.75 (most
likely), or ?1.0 (very likely).
To exemplify, we chose both easy problems and prob-
lems requiring extensive comments and where the result of
the analyses remains open for discussion. Our judgment of
the evidence, indicated as CTv(a) and CTf(a), is given in
Table 1 together with the calculated Vs(a).
Results and comments
Does dilation of larger cranial arteries cause
the pain in migraine headache?
Extracranial arterial vasodilation is traditionally regarded
as the cause of migraine headache [15, 16]. Increased
temporal pulsations were observed during migraine, and
these pulsations decreased after intravenous ergotamine
in parallel with the effect on headache [15]. Decreased
blood velocity in the middle cerebral artery (MCA) dur-
ing migraine, measured with transcranial Doppler (TCD),
was found [17]. Since the cerebral blood flow was
unchanged, it indicated dilation of the MCA [17]. This
finding was confirmed with TCD in two small studies
in 25 [18] and 10 [19] patients, respectively. The CTv(a)
is 1.0.
In two relatively large studies with 31 [20] and 51 [21]
patients, respectively, no decrease in blood flow velocity
was found with TCD during migraine attacks. Furthermore,
a recent magnetic resonance angiography (MRA) study
found no MCA or extracranial part of the middle menin-
geal artery (MMA) dilatation during nitroglycerin-induced
migraine (n = 20) [22]. Arguably, a negative study could
theoretically be caused by variability in measurements, but
in the MRA study [22], MMA (17%) and MCA (11%)
vasodilation was observed during the 20-min infusion of
nitroglycerin. We judge the CTf(a) to be 1.0. The verdict is
still out concerning large cranial artery vasodilatation
during migraine and the verisimilitude is 0.
Is calcitonin gene-related peptide (CGRP) increased
in the external jugular vein (EJV) during migraine
attacks?
For many years it has been known that CGRP is increased
in the EJV blood during migraine attacks [23, 24] leading
to the conclusion that CGRP is a neuropeptide elevated
during migraine attacks [25]. In a study of very long-
standing attacks (median 11 h), sumatriptan treatment
normalized CGRP levels [24]. The CTv(a) is 1.0.
Calcitonin gene-related peptide (CGRP) was unchanged
in two spontaneous migraine studies [26, 27]. Both the
studies used intra-patient design [26, 27]. In one study [26],
two CGRP analyses methods were used including a method
used previously by Goadsby et al. [23, 24], but no change
in CGRP was observed. Furthermore, in one nitroglycerin-
induced migraine attack study, CGRP was not increased
[27]. The CTf(a) is 1.0. Currently, there is similar evidence
for and against increased CGRP in the EJV, and the veri-
similitude is 0.
Is migraine a dysfunction of the sensory modulatory
network?
Most neurologists agree that migraine starts in the brain
and confer the prodromes and aura, but their opinions about
the headache phase differ. Recently, a proponent of pure
CNS pathophysiology stated, ‘‘Migraine is a dysfunction of
the sensory modulatory network with the dominant dis-
turbance affecting abnormal processing of essentially nor-
mal neuronal traffic’’ [7].
The prodromes that occur in 30% of patients [28] and
auras that occur in 20% of patients [29] must originate in
the CNS. During aura, there is a characteristic spreading
oligemia in the cerebral cortex [30–32]. Other evidence for
CNS involvement during migraine attacks is available.
Persistent brain stem activation was observed by PET
during migraine attack [4, 33, 34]. Additionally, hypotha-
lamic activation is observed during migraine attacks [34].
Few cases of symptomatic migraine caused by brain stem
lesions are reported [35, 36]. Other migraine symptoms,
such as photo- and phonophobia, are without peripheral
cause [7]. b-blockers used as migraine prophylactics
probably exert their effect in the CNS [37]. Valproate and
topiramate also probably work in the CNS [29]. In rats,
chronically administered prophylactic migraine drugs like
propranolol, valproate, topiramate amitriptyline, and
methysergide suppressed CSD frequency and increased the
cathodal stimulation threshold required to evoke CSD [38].
Additionally, 5-HT1B/1D receptors are present in the
brain stem [39], which could explain the efficacy of trip-
tans and alkaloids in migraine. There are many pros and the
CTv(a) is 1.0.
In an animal model of migraine, c-fos expression and
the ‘‘evoked potential’’ are observed in the trigeminal
nucleus caudalis (TNC) after superior sagittal sinus stim-
ulation in the cat [40–43]. There appears to be a peripheral
source for this ‘‘brain stem’’ activity in the animal migraine
model. CSD activates trigeminal afferents, resulting in a
series of cortical, meningeal, and brain stem events con-
sistent with the development of a process similar to
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Table 1 Verisimilitude calculations for proposed migraine and cluster headache mechanisms (for details, see text)
Hypothesis (prediction)
Vs(a) CTv(a) CTf(a)
Vasodilation of large cranial arteries is involved in migraine pain
Vasodilation of large arteries during
migraine is undecided (0)
Increased temporal pulsations during migraine
and the effect of ergotamine [15]. Decreased
blood velocity in MCA during migraine
measured with TCD [17–19] (1.0)
No change in MCA velocity measured with
TCD [20, 21] No vasodilatation measured
directly with MCA in MMA and MCA during
NTG-induced migraine [22] (1.0)
Calcitonin gene-related peptide (CGRP) is increased in the external jugular vein (EJV) during migraine
CGRP increase in EJV during migraine
remains undecided (0)
CGRP was increased in EJV in two studies
[23, 24]. In one study, sumatriptan treatment
normalized CGRP levels [24] (1.0)
CGRP was unchanged in two studies on
spontaneous migraine [26, 27] and one study
in nitroglycerin-induced migraine [27] (1.0)
Migraine is a dysfunction of the sensory modulatory network with the dominant disturbance affecting abnormal processing of essentially normal
neuronal traffic [7]
Whether a migraine attack is a pure neuronal
process without vascular components
being involved is unresolved (0). See text
A migraine attack must start in the brain to
cause the prodromes and aura. Persistent
activation in the brain stem is observed by
PET during migraine attack [4, 33]. Few
cases of symptomatic migraine are caused by
brain stem lesions [35, 36]. Other migraine
symptoms, photo- and phonophobia, have no
peripheral cause [7]. The b-blockers used in
migraine prophylaxis probably exert their
effect in the CNS [37]. Valproate and
topiramate also most likely work in the CNS
[29] (1.0)
C-fos expression and ‘‘evoked potential’’ are
observed in TNC after superior sagittal sinus
stimulation in the cat model of migraine.
[42]. There may be a peripheral source for
activity. No other part of the body
experiences pain without nociceptive input,
except thalamic pain and other neuronal
lesions with sensory sign [129]. A pure
neuronal disorder does not explain the co-
morbidities of migraine with aura and stroke
and ischemic heart disease [48, 49, 129]; a
vascular or systemic factor must be involved.
A central theory would not explain possible
CGRP increases in EJV [23, 24]. Systemic
endothelial dysfunction present in migraine
[127] (1.0)
Does aura trigger headache in migraine attacks?
Aura is likely to trigger a migraine attack
(?0.25)
Clinically, the headache in migraine is
contralateral to aura in 92% [58]
Experimentally, CSD activates trigeminal
afferents and evokes a series of cortical
meningeal and brain stem events consistent
with headache development in rats [44]. CSD
activates matrix metalloproteinase, which
opens the blood–brain barrier [62] (0.75)
Clinically, there are well-documented cases of
headache ipsilateral to aura [57]. Patients
with aura but no headache challenge the
notion that aura causes headache. [57]. Aura
does not necessarily precede headache [57].
Experimentally, no correlation between CSD
and neurogenic inflammation and nociception
in rats. [66] (0.5)
Brain stem activation occurs during spontaneous and provoked migraine attacks
Brain stem most likely activated during
migraine, but lateralization doubtful;
pathophysiological implications somewhat
unclear. (?0.75)
Two PET studies in spontaneous [33, 34] and
one in NTG-induced migraine [4], showed
brain stem activation which persisted after
sumatriptan treatment [4, 33, 34] (1.0)
Lateralization of activation and pain is
inconsistent. In one study, PET activation
was ipsilateral [4], in two others contralateral
[33, 34] or bilateral [34] to pain (0.25)
Regional cerebral blood flow (rCBF) is normal in migraine without aura
No firm conclusions (0) rCBF measurements were normal in one
SPECT study [68]. Brain stem activated in
migraine but no occipital hypoperfusion
observed by PET [4, 34]. Normal rCBF
measured with PWI [69] (1.0)
Occipital hypoperfusion was observed with
PET (n = 6) [73]. Spreading oligemia
observed with PET in one case [74]. A
SPECT study showed focal hypoperfusion in
74% of patients [70]. Patchy hypoperfusion
was observed [71]. Small general reduction
of CBF [72] (1.0)
NO is involved in migraine pathophysiology. iNOS inhibitors will be effective migraine prophylactics
NO is likely involved in migraine (?0.5) Nitroglycerin induces genuine migraine attacks
[22, 75–83]. L-NMMA is effective in
migraine [84] (1.0)
INOS inhibitors (GW273629, GW274150)
were ineffective in treating migraine attacks
[85, 86]. GW274150 was ineffective as a
prophylactic agent [86, 87] (0.25)
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headache pain transmitted by the trigeminal nerve in this
animal model of migraine with aura [44]. In another study,
CSD directly activated trigeminovascular nociceptors
without perivascular meningeal inflammation (the dura
mater was not examined) [45].
If the carotid artery is occluded ipsilateral to the side of
migraine headache then two-thirds will experience relief
[46] indicating that cranial arteries are involved in migraine
pain. The co-morbidities of migraine with aura and stroke,
ischemic heart disease, and cervical arterial dissection [47–
53] indicate a vascular or systemic component in migraine.
The possible increased release of CGRP [23, 24, 54] in the
external jugular vein is probably due to CGRP released
locally from perivascular nerves. The small possible
‘‘infarcts’’ observed with MRI in the posterior cerebral
circulation [55] indicate a vascular genesis. Brachial artery
diameter (mean 4.82 vs. 5.39 mm) and compliance (mean
0.30 vs. 0.37 mm2/kPa) were decreased in migraine
patients compared with controls [56]. Carotid arterial wall
properties were similar between groups [56]. The CTf(a)
was 1.0 and the verisimilitude was 0.
Does aura trigger the headache in migraine attacks?
The relationship between aura and headache in migraine
with aura has been questioned [57]. Some clinical evidence
for a relationship exists. Thus, 35 (92%, 95 CI: 79–98%)
out of 38 patients in whom both aura and headache were
unilateral, felt that the headache and the aura were con-
tralateral to each other; i.e. the headache was perceived
over the affected hemisphere [58]. Aura and headache were
perceived as ipsilateral only in 3 patients. Notably, the
results were obtained with prospective-symptom recording.
As much as 19 patients had bilateral headache and could
not provide evidence on whether or not aura triggers
headache [58].
Experimentally, CSD activates trigeminal afferents and
evokes a series of cortical meningeal and brain stem events
[44]. Several other animal studies showed that CSD can
cause activation of the brain stem [59–61]. CSD activates
matrix metalloproteinases, which open the blood–brain
barrier [62]. In one study, activation of trigeminovascular
nociceptors by CSD occurred without perivascular
inflammation [45]. Neurogenic inflammation is, however,
unlikely to be involved in migraine pain or in the link
between aura and headache. Overall the CTv(a) is 1.0.
A clinical argument against aura as a migraine trigger is
that most migraineurs never experience aura [29, 63], but the
headache phase is, in principle, the same in migraine with or
without aura [29]. Additionally, there are well-documented
cases of headache ipsilateral to aura [57]. Patients with aura,
but no headache are not uncommon [64, 65], challenging [57,
63] the notion that aura causes headache. Aura does not nec-
essarily precede headache [57].
Experimental evidence against aura as a trigger of
migraine pain comes from two studies in which there was
no activation or sensitization of second-order neurons in
TNC by CSD [66, 67]. The CTf(a) is 0.5.
I believe aura is likely to trigger a migraine attack, and




Dural neurogenic inflammation (NI) is involved in migraine, predicting effectiveness of NI inhibitors in migraine
NI unlikely to have a pivotal role in migraine
pain (–0.5)
Endothelin and NK-1 receptor antagonists
effectively inhibit NI in animal studies
[94, 95]. In addition, triptans and ergot
alkaloids inhibits NI [90, 91] (0.5)
Randomized clinical trials show no effect of
substance P, neurokinin-1 antagonists
[96–98], neurosteroid ganaxolone [99],
endothelin antagonist [100], or specific NI
blockers [101, 102] (1.0)
Aura is common in cluster headache patients [Schu¨rks-et al-2006]a
Aura must be rare in cluster headache (-0.5) Aura occurred in 4% [106],14% [103], 23%
[104], and 28% [105] of cluster headache
patients (0.5)
None of 554 cluster headache patients
experienced aura [111] (1.0)
Hypothalamic activation is specific for cluster headache and other trigeminal autonomic cephalalgia (TAC) [133]
Hypothalamic activation is not cluster
headache specific; the Popper falsification
rule [8] was used
Activation in the posterior hypothalamus
during nitroglycerin-induced cluster
headache attacks was observed by PET
[112, 113]. In migraine without aura, no
hypothalamic activation was found in two
PET studies [4, 33]. In two SUNCT patients,
functional MRI identified hypothalamic
activation [116, 117]
Activation was observed in both the
hypothalamus and brain stem (n = 7) with
PET [34]
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Is brain stem activation measured with PET present
during migraine attacks?
In three PET studies, brain stem activation was observed
[4, 33, 34]. This activation persisted after treatment with
sumatriptan [4, 33, 34]. Therefore, in all PET studies
conducted so far, brain stem activation was found and the
CTv(a) is 1.0. However, there is an unexplained inconsis-
tency concerning the lateralization of activation and pain.
In one study, PET activation was ipsilateral to pain [4],
whereas it was contralateral [33, 34] or bilateral [34] to
pain in others. The CTf(a) is 0.25. Brain stem activation
during migraine is probable. However, lateralization is
doubtful, making the pathophysiological implications
unclear and the final verisimilitude is ?0.75.
Is regional cerebral blood flow (rCBF) normal
during attacks of migraine without aura?
rCBF, measured with SPECT, was normal before and
during 8 wine-induced migraines without aura attacks
[68]. In two PET studies in migraine without aura attacks
in either spontaneous (n = 9) [33] or GTN-induced
(n = 24) [4] attacks, there was no occipital hypoperfu-
sion. During spontaneous migraine attacks with a duration
of 1–11 h, perfusion-weighted imaging reveals normal
hemodynamic (n = 13) [69]. The CTv(a) is judged to
be 1.0.
rCBF during spontaneous/induced migraine without
aura attacks were investigated with SPECT (n = 35) [70]
and 74% of patients displayed an unilateral hypoperfusion,
mainly in the occipital region. In one PET study, there was
generally no change in rCBF, but analysis of individual
data showed patchy hypoperfusion in the temporo/occipital
region in 4 patients with migraine without aura [71].
Global CBF was slightly, but significantly reduced in
migraine without aura attacks compared with outside
attacks (n = 9), 53 versus 60 ml/min/100 g, respectively
[72]. Occipital hypoperfusion was observed in another PET
investigation in established attacks without aura (n = 6)
[73]. Spreading oligemia was observed with PET in one
case [74]. The resulting CTf(a) is most likely 1.0. Thus, no
firm conclusion concerning rCBF in migraine without aura
can presently be drawn and the verisimilitude is 0.
Is NO involved in migraine pathophysiology?
Glyceryl trinitrate induced migraine without aura with a
latency of some hours in migraine sufferers, with and
without aura, in 11 studies [2, 22, 75–83]. A double-blind,
placebo-controlled design was used in two investigations
[22, 78]. The NOS inhibitor, L-NMMA effectively treated
migraine attacks [84]. The CTv(a) is 1.0.
However, the two iNOS inhibitors GW274150 and
GW273629 were ineffective in treating migraine attacks in
one placebo-controlled study (n = 126) [85] and in an
open-label pharmacokinetic study [86]. Additionally,
GW274150 was ineffective in a double-blind, placebo-
controlled study as a prophylactic agent for migraine
(n = 430) [87]. Since other NOS isoforms (nNOS and
eNOS) may be involved in the effect of NO [88], the
CTf(a) is 0.25.
NO is most likely involved in the pathophysiology of
migraine with a verisimilitude of ?0.75.
Is neurogenic inflammation (NI) involved
in the headache aspect of migraine?
If dural NI is involved in migraine, as proposed by
Markowitz et al. [89], NI inhibitors would be predicted to
be effective in migraine. This is true to some extent
because ergot alkaloids and triptan inhibit NI [90, 91].
These drugs are, however, not specific NI inhibitors
[92, 93]; however, endothelin and NK-1 receptor antago-
nists effectively inhibit NI in animal studies [94, 95]. The
CTv(a) is 0.5.
Alternatively, several randomized clinical trials show no
effect of substance P, neurokinin-1 antagonists [96–98],
neurosteroid ganaxolone [99], endothelin antagonists
[100], or the specific NI blockers CP122,288 and 4991w93
[101, 102] in the acute treatment of migraine. The CTf(a) is
1.0.
Since specific NI inhibitors have no effect in migraine, it
is difficult to find a pivotal role for dural NI in migraine
[7, 63] and the verisimilitude is -0.5.
Is aura common in cluster headache attacks?
The next subject is theoretically important. If aura is not
only linked to migraine with aura, but also with other
primary headaches, such as cluster headaches, aura and
migraine could be caused by two different mechanisms
[57, 103]. In a recent paper [104], aura was described as
being common in cluster headaches, with 23% of cluster
headache patients in the study experiencing aura. Simi-
larly, aura was reported in 28% of cluster headache
patients in a series of 76 patients [105]. In two earlier
studies, aura was reported in 4 [106] and 13% [103],
respectively, of cluster headache patients. In 1972, Gra-
ham mentioned that brief episodes of scintillating rarely,
but occasionally occur before cluster headache attacks
[107]. The CTv(a) for aura being common in cluster
headache is thus 0.5.
Dr. Karl Ekbom from Stockholm, Sweden, an expert in
cluster headache [108, 109] and migraine with aura [110],
was asked his opinion. In a series of 554 cluster headache
J Headache Pain (2010) 11:379–389 383
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patients, there were no cases of aura in connection with
cluster headache attacks [111]. The CTf(a) is 1.0.
Aura is, therefore, likely to be rare in cluster headache
patients, and the verisimilitude is -0.5.
Hypothalamic activation is specific for cluster headache
and other trigeminal autonomic cephalalgias
Functional PET imaging shed light on the genesis of
migraine and cluster headache by repeatedly documenting
activation in the midbrain and pons during migraine, and in
the hypothalamus during cluster headache. Two PET
investigations found activation in the posterior hypothala-
mus during nitroglycerin-induced cluster headache attacks
[112, 113]. Voxel-based morphometry with MRI found
changes in the same region [114]. Furthermore, with
1H-MR spectroscopy, hypothalamic-N-acetyl aspartate/
creatinine was reduced in patients with cluster headache
versus controls [115]. In two patients with SUNCT,
hypothalamic activation was observed with functional MRI
[116, 117]. In paroxysmal hemicrania, hypothalamic acti-
vation was found with PET [118]. In hemicrania continua,
with a phenotype in between cluster headache and
migraine, activation was observed both in the hypothala-
mus and in the brain stem [119].
In migraine without aura, hypothalamic activation was
not found in two PET studies (n = 33) [4, 33]. Hypotha-
lamic activation concurrent with brain stem activation was
observed in one PET study in migraine without aura attacks
(n = 7) [34, 73]. These activations persisted after suc-
cessful treatment with sumatriptan [34, 73].
In this case, the Popper falsification rule [8] seems
appropriate. Hypothalamic activation is not specific to
cluster headache because it was observed in migraine
without aura in a study with appropriate PET techniques
[34].
Discussion
Current migraine-mechanism theories vary from the notion
that the migraine attack ‘‘consists of an abnormal percep-
tion of otherwise normal circumstances, such as pain
without evidence of primary nociceptive activation’’ [7] to
‘‘migraine may be a local manifestation of a systematic
vascular abnormality rather than a primary cerebral phe-
nomenon’’ [120] or to ‘‘migraine is a neurovascular dis-
order’’ [121].
Popper’s verisimilitude calculation does not resolve
problems always. Potentially, both the CTv(a) and CTf(a)
can be 1.0 with a resulting verisimilitude of 0. Sometimes,
one must fall back to the Popper falsification method,
where negative facts that can falsify the hypothesis are the
main stay. Migraine data are often not validated well
enough to allow clear-cut conclusions. Particularly, con-
firmatory studies using the same methodology are often
lacking.
In areas like migraine research, which is often descrip-
tive, many cases of contradictory data exist because of both
biological variability per se and different methods of
measuring the biological signal.
No grand unifying theory exists in migraine research
that can be falsified by itself or by its predictions [8],
leaving only isolated relevant problems of basic and clin-
ical migraine research for testing.
When evaluating the problems, we often used a mixture
of facts from both kinds of research. Verisimilitude
determinations can supplement the usual pros and cons by
forcing judgement of the evidence for hypothesis a when
assigning values to CTv(a) and CTf(a) [14]. According to
Popper, Vs(a) calculation is an objective method for
judging a scientific theory or the predictions derived from a
theory [14].
Verisimilitude measures the best correspondence with
facts and should not be confused with probability [14]. One
can apply the simple verisimilitude formula to any field one
knows well. Notably, verisimilitude calculations should not
be applied to quantitative migraine treatment trials when a
systematic review or meta-analysis is more appropriate
[10–13].
Despite efforts at objectivity, some subjectivity remains
in assigning values to Ct(a) and Ctf(a). Some may disagree
with my calculations, but anyone can easily assign alter-
native Ct(a) and Cf(a) values and calculate verisimilitude
for themselves.
Among the 10 cases judged by verisimilitude calcula-
tions, there were two -0.5 (unlikely), four 0 (undecided),
one ?0.25 (probably likely), one ?0.5 (likely), and one
?0.75 (most likely) (Table 1). For one item, the falsifica-
tion ad modum Popper [8] was found to be more suitable.
There was no -1.0 (very unlikely), probably because there
is always some historical or recent evidence for the
hypothesis tested [89–91, 104, 105]. The -0.5 depend on
the formulation of the question. In four cases, we could not
decide whether the theory was true or false because the
evidence for and against it was of equal weight.
The verisimilitude approach is not problem-free. To
illustrate, I discuss two problems in detail: migraine as a
pure CNS disorder, possible aura in cluster headache, and
cortical spreading depression (CSD).
The theory that migraine is a dysfunction of the sensory
modulatory network [7] can be re-formulated as migraine is
a pure human brain disease. Many good arguments exist
for both sides and the CTv(a) and CTf(a) will still be 1.0
with the facts used in my analysis (Table 1), and verisi-
militude will be 0. However, when using my prerogative as
384 J Headache Pain (2010) 11:379–389
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author and using our ‘‘natural instincts’’ (see vignette)
combined with Popper’s falsification theory [8], I believe
that the verisimilitude should be negative.
Thus, the theory that migraine is a brain disease would
predict that there is no non-brain disorder associated with
it. The main falsifying argument of this prediction is the
cardiovascular comorbidity associated with migraine [56].
For example, there is an association between cervical
arterial dissection and migraine, mainly migraine with aura
[52, 53]. Additionally, migraine, particularly migraine with
aura, is a risk factor for ischemic stroke [47, 56]. The
arteries of the systemic circulation were also investigated
[56, 120, 122]. Migraineurs with recent onset (\6 years)
had decreased brachial arterial diameters and compliances
[56]. Decreased flow-mediated dilatation of the brachial
artery was also found in two other studies in migraineurs
[120, 122].
Furthermore, some genetic arteriopathies are associated
with migraine [123, 124] and in CADASIL, where the
notch-3 gene appears to be expressed exclusively in vas-
cular smooth muscles within adult brain [125]. rCBF
changes during migraine were similar in one case to
migraine with aura [6, 126].
Circulating endothelial progenitor cell numbers and
functions (i.e. endothelial repair markers) [127], are
reduced, especially in migraine with aura patients [128]. In
two studies [48, 129], the von Willebrand factor, a plasma
marker of endothelial dysfunction, was increased in
migraine. Thus, there is good evidence that migraine is
associated with endothelial dysfunction, and could be the
underlying link between migraine and cardiovascular risk
[49, 128].
I believe that the arguments against the predictions of
the neuronal theory of migraine falsify this theory [7].
Migraine is unlikely to be a brain-only disease. Another
argument against the neuronal theory is that no other part
of the human body experiences pain without nociceptive
input except thalamic pain and other neuronal lesions
with sensory signs [130]. In migraine, there can be allo-
dynia, but no sensory signs [130]. I believe that, in
addition to a clear CNS component, there is also a
peripheral component in the headache phase. Regarding
the source of pain, Goadsby recently stated ‘‘The pain
process is likely to be a combination of direct factors, i.e.
activation of the nociceptors of pain-producing intracra-
nial structures, in concert with a reduction in the normal
functioning of the endogenous pain control pathways that
normally gate that pain’’ [7]. I agree that there is both a
peripheral and central aspect of migraine headache.
Because of the pulsating pain in migraine, I believe
vascular nociception most likely [131] even though the
verisimilitude of large arterial vasodilation during
migraine was zero.
The question of aura in cluster headache
Four recent papers report prevalences of 4 to 28% for aura
in cluster headache [103–106]. One may wonder how such
a frequent and characteristic phenomenon went unrecog-
nized by Baylor Horton, who described histaminic cepha-
lalgia in 1938 (n = 181) [131]. Horton later in 1956
reported seeing 1,176 patients (1,023 men and 153 women)
with histaminic cephalalgia [133]. Aura is not mentioned
by Kudrow whose book from 1980 included 495 patients
[132]. However, the cluster headache expert John R. Gra-
ham wrote ‘‘Now to our surprise we were able to establish
that in 20 cluster headache patients brief episodes of
scintillating scotoma rarely, but occasionally, did precede
the cluster headache attacks’’ [107]. However, there are
inconsistencies in the prevalences reported. The highest
reported prevalence is 28% (n = 76) [105] and the lowest
is 4% (n = 101) [107], a difference of 24% (95% CI 13–
34%, P \ 0.0001, Fisher’s exact test). The difference
between the 23 [104] and 4% [106] prevalence is 19%
(95% CI 13–26%, P \ 0.0001). Also, prevalence was
significantly different between the two largest studies: 23
(n = 246) [104] versus 13% (n = 230) [103], a difference
of 10% (95% CI 2–16%, P = 0.01). These differences
demonstrate that the method of registering ‘‘so-called
aura’’ must have varied considerably.
In contrast, no reports of aura in cluster headache were
reported in a large series of 554 cluster headache patients
from one Swedish center [111]. Karl Ekbom, who has a
special interest in aura [110], personally interviewed 427
patients, and observed and questioned about 100 of them
during spontaneous or provoked cluster headache attacks
[111].
Confronted with these incomparable data, it is a matter
of belief or trust. Both sets of contradictory data cannot be
an approximation of the truth and I calculated the verisi-
militude to be -0.5. In my opinion, aura must be rare
among cluster headache patients.
In conclusion, I believe verisimilitude calculations are
suitable for many migraine and cluster headache mecha-
nism problems. Contradictory data concerning a specific
problem are common and a verisimilitude calculation
enforces a qualitative judgement of the data. Sometimes,
the resulting verisimilitude is zero, but both, CTv(a) and
CTf(a), cannot be an approximation of the truth. In some
cases, further investigation is needed or a clearer hypoth-
esis should be formulated, and appropriate investigations
aimed at falsifying the thesis [8] should be performed.
Finally, positive evidence is never conclusive; but neither
is negative evidence, nor would it be a good idea to pretend
that it was [1].
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